NeoTX Therapeutics

Share on: 
Description: 

NeoTX uses its Selective T cell Redirection (STR) platform to develop new targeted anticancer immunotherapies. STR binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating immune cells away from the suppressive tumor environment to mount an effective antibacterial response. The technology effectively converts a weak immune response against the tumor to a powerful, yet safe, native antibacterial immune reaction.

Career Page(s): 
Location(s): 
Rehovot
Israel